VANCOUVER, British Columbia, May 28, 2018 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (TSX-V:CBW) ("Cannabis Wheaton" or the "Company") is pleased to announce that its previously announced streaming partner, FV Pharma Inc. ("FV Pharma"), now a wholly-owned subsidiary of FSD Pharma Inc. ("FSD Pharma"), has received all of the necessary exchange and regulatory approvals to commence trading publicly on the Canadian Securities Exchange ("CSE") under the symbol "HUGE" and is expected to commence trading May 29, 2018.



FV Pharma is a licensed producer to cultivate cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations ("ACMPR") that owns and operates the former Kraft® food production facility in Cobourg, Ontario (the "Facility"). The Facility boasts an existing 620,000 square feet of building space on 70 acres of land and is currently cultivating medical cannabis in an initial 20,000 square foot footprint.

Pursuant to the Company’s agreement with FV Pharma, in exchange for access to the Cannabis Wheaton platform which includes ongoing financial, design and operational support and expertise, Cannabis Wheaton will receive a 49.9% stream of all cannabis (or cannabis-derived products including any immature cannabis plants and any cannabis trim) produced at the Facility, under partnership with Cannabis Wheaton, in perpetuity.

The Company is also pleased to announce that Vlad Klacar, Associate General Counsel and Head of Regulatory Affairs at Cannabis Wheaton has been appointed to the board of directors of FSD Pharma.

Chuck Rifici, Chairman and Chief Executive Officer of Cannabis Wheaton commented, "Becoming publicly traded marks a milestone achievement for the team at FSD Pharma and we congratulate them on their many successes to date. We look forward to breaking ground on the first stage of a 200,000 sq. ft. initial footprint in 2018, for which blueprint renderings are now complete and working with FSD Pharma to create a truly differentiated indoor growing facility."

ON BEHALF OF THE BOARD

"Chuck Rifici" Chairman & CEO

About Cannabis Wheaton (TSX-V:CBW)

Cannabis Wheaton is a collective of entrepreneurs with a passion for the cannabis industry past, present and future. Our mandate is to facilitate growth for our partners by providing them with financial support and sharing our collective industry experience. Our partners all have different visions, voices and brand values, and all share a common goal—to build a world-class industry based on ethics, diversity, quality and innovation.

Investor Relations:

For more information about investing in Cannabis Wheaton, please visit: http://www.wheatonincome.com or contact our Investor Relations Team:

Email: IR@wheatonincome.com

Phone: 800.980.1314

Stay Connected:

Follow up on Twitter @WheatonIncome.

Media Enquiries (only):

For media enquiries or to set up an interview please contact:

Sarah Bain, VP External Affairs

Email: sarah@wheatonincome.com

Phone: 613.230.5869

About FSD Pharma

FSD Pharma, owns, through its wholly-owned subsidiary FV Pharma Inc., a license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) which was originally granted on October 13, 2017. Headquartered at the former Kraft plant in Cobourg, Ontario, approximately an hour’s drive from Toronto, FSD Pharma's management’s mission is to transform the facility into the largest hydroponic indoor cannabis facility in the world. FSD Pharma intends to target all legal aspects of the cannabis industry, including cultivation, processing, manufacturing, extracts and research and development. Please visit www.fsdpharma.com for more information.

Stay Connected:

For further information about FV Pharma Inc. and our management team, please visit: www.fsdpharma.com or contact Thomas Fairfull ((905) 686-7079 or thomas@fvpharma.com or Zeeshan Saeed (416-854-8884) or zeeshan@fsdpharma.com).

Investor Relations:

For more information about investing in FSD Pharma, please visit: www.fsdpharma.com or contact our Investor Relations Team:

Email: zach@fsdpharma.com

Phone: 647-980-7541

Notice Regarding Forward Looking Statements:

This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: expectations of future growing capacity at the Facility and the projected costs associated with each expansion phase of the Facility; the completion of the planned build-out and expansion phases; the funding requirements for each expansion phase; the projected revenue achievable by the Facility; and the proposed licensing of the Facility and the expected timing to obtain all necessary licenses required for the proposed operation of the Facility. By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company or the Facility to be materially different from those expressed or implied by such information and statements.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to, whether: sufficient funding can be obtained to complete each phased expansion of the Facility in the manner proposed or at all; the Company and FV Pharma can satisfy the conditions associated with the Facility’s cultivation license; a sales authorization can be obtained for the license and the related timing considerations; the Company and FV Pharma can obtain all necessary governmental and regulatory permits and approvals for the Facility, including in relation to the construction of each proposed expansion phase, and whether such permits and approvals can be obtained in a timely manner; FV Pharma complies with its obligations under the Agreement; the Facility can be operated as intended; current and future management will abide by the investment objectives and investment strategies of the Company; the Company will supplement its board of directors and management, or otherwise engage consultants and advisors, having knowledge of the industries in which the Company invests; streaming partners will be able to generate cash flow; general economic, financial market, regulatory and political conditions in which the Company operates will remain the same; the Company will be able to compete in the industry; the Company will be able to manage anticipated and unanticipated costs; the Company will be able to enter into additional streaming agreements; the Company will be able to maintain internal controls over financial reporting and disclosure, controls and procedures; streaming partners will be able to meet the requirements necessary to obtain and / or maintain their status as licensed entities; and streaming partners will be able to successfully complete initial construction and / or expansion construction of their respective facilities pursuant to the terms and conditions of their respective streaming agreements. Additional risk factors are disclosed in the revised annual information form of the Company for the financial year ended December 31, 2017 dated May 24, 2018.

New factors emerge from time to time, and it is not possible for management to predict all of those factors or to assess in advance the impact of each such factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. In addition, this release may contain forward-looking information attributed to third party industry sources, the accuracy of which has not been verified by the Company. The purpose of forward-looking information is to provide the reader with a description of management's expectations, and such forward-looking information may not be appropriate for any other purpose. Readers should not place undue reliance on forward-looking information contained in this release.

The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.